Business Context and Reporting Period
This Form 8-K was filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on October 25, 2013. The report details a significant capital raising event involving the issuance of common stock.
Key Financial Metrics
- Shares Issued: 4,375,000 shares of Common Stock.
- Offering Price: $8.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 656,250 shares.
- Net Proceeds: Approximately $32.7 million (excluding potential over-allotment proceeds), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Expected Closing Date: On or about October 30, 2013.
Material Changes
The filing reports the execution of an underwriting agreement with Stifel, Nicolaus & Company, Incorporated and Cowen and Company, LLC. This represents a material change in the company's capital structure and liquidity position pending the closing of the transaction.
Outlook and Management Commentary
The offering is being made pursuant to effective registration statements on Form S-3 (Nos. 333-173266 and 333-191893). The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions. A press release announcing the pricing was issued on October 25, 2013.
Investor Verification Checklist
- Verify the final closing date of the offering (expected October 30, 2013).
- Confirm whether the underwriters exercised the 30-day over-allotment option for an additional 656,250 shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific conditions to closing.
- Check the press release (Exhibit 99.1) for the stated use of proceeds.